Samsung Bioepis starts to develop new drug for acute pancreatitis
Samsung Bioepis(CEO/President Han-Seung Ko) will start to develop new drugs for acute pancreatitis.
Samsung Bioepis said they would conduct a Phase I clinical trial for an acute pancreatitis therapy candidate(project name: SB26, TAK-671) being developed jointly with Japanese Takeda Pharmaceutica...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.